An injectable, in situ enzymatically gellable, gelatin derivative for drug delivery and tissue engineering
An injectable, in situ enzymatically gellable, gelatin derivative for drug delivery and tissue engineering
复制标题
DOI：
10.1016/j.biomaterials.2009.03.030
复制
发表时间：
2009-07-01
期刊：
影响因子：
14
通讯作者：
Kawakami, Koei
中科院分区：
文献类型：
--
作者：
Sakai, Shinji;Hirose, Keisuke;Kawakami, Koei
利用水相碳二亚胺活化化学，将酚羟基掺入明胶中，获得可原位凝胶化和可注射的蛋白质基材料，用于药物输送和组织工程应用。通过这种方法，获得了可通过过氧化物酶催化反应凝胶化的明胶衍生物。酶交联明胶在37℃下不熔化，并表现出可调节的蛋白水解降解性。胶凝所需时间随酚羟基（Ph）基团含量、过氧化物酶浓度和H(2)O(2)浓度的增加而减少。凝胶抗压能力也与Ph基团的含量有关，Ph基团含量最低的凝胶抗压能力最强。我们将L929成纤维细胞包封在明胶中，在诱导凝胶化的条件下约10 s。包被细胞的存活率约为95%。此外，接种在凝胶上的L929细胞与接种在未修饰的明胶包被培养皿上的细胞表现出相同的生长特征。啮齿类动物皮下注射实验表明，在注射部位成功地原位形成凝胶。(c) 2009 Elsevier Ltd.版权所有。
A phenolic hydroxyl group was incorporated into gelatin, using aqueous-phase carbodiimide activation chemistry, to obtain in situ gellable and injectable protein-based materials for drug delivery and tissue engineering applications. By this means, gelatin derivatives that were gellable via a peroxidase-catalyzed reaction were obtained. The enzymatically cross-linked gelatin gels did not melt at 37 degrees C and showed tunable proteolytic degradability. The time necessary for gelation decreased with increasing content of the phenolic hydroxyl (Ph) group, peroxidase concentration and decreasing H(2)O(2) concentration. Resistance to gel compression also depended on the content of Ph groups, with the gel containing the lowest Ph group content showing the greatest resistance to compression. We encapsulated L929 fibroblast cells in gelatin gels under conditions that induced gelation in about 10 s. The encapsulated cells showed about 95% viability. In addition, L929 cells seeded on the gels showed the same growth profiles as those seeded on an unmodified gelatin-coated dish. Subcutaneous rodent injection experiments demonstrated successful in situ formation of gels at the injected site. (c) 2009 Elsevier Ltd. All rights reserved.